Abstract 24P
Background
Identifying biomarkers for mRCC is an unmet need in actual immunotherapy (IO) era. Available data regarding chromosome 3p-related genes (i.e., VHL, PBRM1, SETD2) as potential predictors for therapy response is conflicting. We describe the correlation of these GA with clinical outcomes in mRCC pts treated with IO/IO or IO/tyrosine kinase inhibitor (TKI).
Methods
We performed a single-center retrospective analysis on mRCC pts treated with first line IO/IO or IO/TKI. A multi-gene panel was used, allowing the amplification of 841 amplicons (54.93kb, human reference sequence hg19/GRCh37) in the coding sequences of the following genes: ATM, BAP1, KDM5C, MET, MTOR, NF2, PBRM1, PIK3CA, PTEN, SETD2, SMARCB1, TP53, TSC1, TSC2, VHL.
Results
30 mRCC pts undergoing IO/IO and IO/TKI were included. Of these, 18 had tumor tissue adequate for molecular analysis: 77.8% male, 22.2% female. Histology was 100% clear cell. IMDC risk was 50% intermediate, 33.4% good, 16.6% poor. First line therapy was 89% IO/TKI, 11% IO/IO. 83.3% pts (n=15) carried GA, among which 61.1% had a known pathogenic mutation (PAT). Most common GA included VHL in 44% (n=8; 7 PAT and 1 variant of unknown significance - VUS), PBRM1 in 44% (n=8; 5 PAT and 3 VUS) and SETD2 in 33% (n=6; 4 PAT and 2 VUS). With the limit of a small sample that did not allow proper statistical analyses, SETD2 mutated pts had lower median progression free (mPFS) and overall survival (mOS) than non-SETD2 mutated pts. Higher mPFS and mOS were shown with VHL or PBRM1 GA, especially in PBRM1+VHL mutated pts (Table). Of note, all PBRM1+VHL mutated pts underwent IO/TKI. Table: 24P
mPFS (months) | mOS (months) | |||
Mutated | Non-mutated | Mutated | Non-mutated | |
SETD2 | 12 | 14.5 | 15 | 16 |
VHL | 19 | 11 | 20 | 14 |
PBRM1 | 19 | 7.5 | 20 | 13 |
PBRM1+VHL | 20 | 7.5 | 20.5 | 13.5 |
Conclusions
Our data shows a possible negative predictive role of SETD2 GA for IO-based therapy in RCC. Concomitant VHL and PBRM1 GA could act as a predictor for IO/TKI efficacy. Our hypothesis-generating analysis highlights the need of an integrated evaluation of these genes as promising biomarkers in RCC. Further larger studies are required.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
200P - A novel multi-organ on chip model for metastatic tumor biology understanding
Presenter: Elisabetta Palama
Session: Poster Display
201P - Role of aerobic exercise training on the mitochondrial metabolism and effector function of CD8+ tumor-infiltrating lymphocytes
Presenter: Janaina Vieira
Session: Poster Display
202P - Discovery of immunological cellular neighborhoods from protein markers in spatial tumor data
Presenter: Marcin Mozejko
Session: Poster Display
203P - Identification of High Confidence Candidate Markers for Macrophage Infiltrating Tumor Microenvironment through Single Cell Genomic Atlases
Presenter: Constance Ciaudo Beyer
Session: Poster Display
204P - Effect of STAT6 Inhibition as a Novel Strategy for Promoting the Induction of Potent and Stable Regulatory T Cells for Use in Colitis Therapy
Presenter: SONIA LEON-CABRERA
Session: Poster Display